RxDoctor Payments Data

Esther Levin, MD

Cardiovascular Disease · Coral Gables, FLNPI 1013926906

Payments from drug & device makers

$2,894in general payments, 2019–2025

Across 123 payments — averaging $23.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$745
  • Arbor Pharmaceuticals, Inc.$371
  • Boehringer Ingelheim$351
  • Azurity Pharmaceuticals, Inc.$247
  • Takeda Pharmaceuticals U.S.A., Inc.$194
  • Boston Scientific$175
  • plus $812 from 14 others

What the payments were for

  • Food & beverage$2,894100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,894 in reported general payments places this provider in the 45th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$104,117
Medicare patients
134
Services billed
963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide83$89,717
EliquisApixaban40$41,007
VascepaIcosapent Ethyl34$20,336
XareltoRivaroxaban19$19,930
WegovySemaglutide11$16,193
LivaloPitavastatin Calcium18$13,585
Repatha SyringeEvolocumab14$12,826
JardianceEmpagliflozin14$9,568
LinzessLinaclotide11$8,969
Rosuvastatin Calcium195$2,750
Nebivolol Hcl28$2,152
Ezetimibe49$2,007
Telmisartan68$1,951
Vilazodone Hcl13$1,859
PaxlovidNirmatrelvir/Ritonavir15$1,377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$745$105,91094 claims
Kowa Pharmaceuticals America, Inc.Livalo$33$13,58518 claims
Boehringer IngelheimJardiance$351$9,56814 claims
AbbVieLinzess$45$8,96911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Coral Gables

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →